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Recent results indicate that proinsulin C-peptide, contrary to previous views, exerts important physiological eﬀects and shows the
characteristics of a bioactive peptide. Studies in type 1 diabetes, involving animal models as well as patients, demonstrate that C-
peptide in replacement doses has the ability to improve peripheral nerve function and prevent or reverse the development of nerve
structuralabnormalities.Peripheralnervefunction,asevaluated bydeterminationofsensorynerveconductionvelocity andquan-
titative sensory testing, is improved by C-peptide replacement in diabetes type 1 patients with early stage neuropathy. Similarly,
autonomic nerve dysfunction is ameliorated following administration of C-peptide for up to 3 months. As evaluated in animal
models of type 1 diabetes, the improved nerve function is accompanied by reversal or prevention of nerve structural changes, and
the mechanisms of action are related to the ability of C-peptide to correct diabetes-induced reductions in endoneurial blood ﬂow
and in Na
+,K
+-ATPase activity and modulation of neurotrophic factors. Combining the results demonstrates that C-peptide may
be a possible new treatment of neuropathy in type 1 diabetes.
Copyright © 2008 K. Ekberg and B.-L. Johansson. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Neuropathy is one of the most common long-term compli-
cations accompanying diabetes mellitus. It aﬀects patients
with both type 1 and type 2 diabetes, but it progresses more
rapidly and its manifestations are more severe in type 1 di-
abetes [1, 2]. Diabetic neuropathy is deﬁned by the pres-
ence of detectable sensory, motor, and autonomic deﬁcits on
clinical examination, with or without the presence of symp-
toms [3, 4]. As many as 50% of the patients may be asymp-
tomatic, diagnosis may only be made on examination or, in
some cases, when the patient presents with a painless foot ul-
cer [5]. Other patients may not volunteer symptoms but on
inquiry admit that their feet feel numb or dead. A thorough
neurological examination of the lower limb usually reveals
sensory loss of vibration, pressure, pain, and temperature
perception mediated by small and large ﬁbers, and absent
ankle reﬂexes. In addition to manifestations of autonomic
neuropathy, for example, impaired cardiovascular and gas-
trointestinal functions, signs of peripheral sympathetic auto-
nomic dysfunction are also frequently seen in patients with
diabetes and may include a warm or cold foot, sometimes
withdistendeddorsalfootveins,dryskin,andthepresenceof
calluses under pressure-bearing areas. Diabetic neuropathies
may present as rapidly reversible hyperglycemic neuropathy
and focal or multifocal neuropathies, but the most relevant
clinical form is the persistent distal symmetric polyneuropa-
thy (DSPN) [4].
The DSPN is characterized as a gradual progression in
structural changes consisting of distal axonal degeneration
of “dying-back” type [6, 7] most prominent in the lower
limbs, but involves also small ﬁber sensory dysfunction early
in the course of the condition [7]. The prevalence of DSPN
is approximately 30% for diabetes patients in general [8],
but the number varies greatly in the literature related to the
deﬁnition chosen for presence of diabetic neuropathy and
the methodology chosen to assess its presence. Clinical ex-
aminations and patients’ symptom assessment are consid-
ered important tools in the evaluation of neuropathy sta-
tus, but both techniques rely greatly on subjective compo-
nents and have thus poor reproducibility and speciﬁcity. As-
sessments using more objective markers of polyneuropathy,2 Experimental Diabetes Research
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Figure 1: Change in peak sensory nerve conduction velocity in the
sural nerves following 3–6 months of C-peptide replacement treat-
ment (red bar) or placebo (gray bar) to patients with type 1 dia-
betes. The ﬁgure presents pooled data from [19, 20].
such as especially nerve conduction velocity (NCV) but also
vibration perception threshold (VPT), may serve not only
as reliable methods for detection of neuropathy, but the re-
sult may also be used for the prediction of mortality in dia-
betic patients [9, 10]. The pathogenesis of diabetic neuropa-
thy involves metabolic eﬀects mediated directly and indi-
rectly by hyperglycemia, resulting in oxidative stress, acceler-
ated polyol pathway metabolism and generation of advanced
glycation endproducts [11–13]. Furthermore, diabetic neu-
ropathy is accompanied by reduced nerve Na+,K+-ATPase
activity, and microvascular abnormalities (e.g., reduced en-
doneurial perfusion) [14]. Type 1 diabetes is associated with
speciﬁc structural nerve abnormalities that are not frequent
in type 2 diabetes. These abnormalities include axonal at-
rophy and characteristic nodal and paranodal changes that
contribute to the progressive deterioration of nerve conduc-
tion velocity [15–17]. In contrast, in type 2 diabetes the ax-
onal degeneration is milder and no or only minimal nodal
and paranodal abnormalities occur [17, 18]. However, after
several years type 2 diabetes often become insulin and C-
peptide deﬁcient, and at this stage it is most likely that the
type 2 DSPN will start presenting with characteristics similar
to that of type 1 neuropathy.
In the case of type 1 diabetes, available data suggest
thatC-peptidedeﬁciencyisanimportantcontributingfactor
to the characteristic structural abnormalities [21]. In con-
formity with this hypothesis several studies have demon-
strated that it is possible to retard the progression of diabetic
complications by intensiﬁed insulin treatment and improved
metaboliccontrol,butdevelopmentofneuropathycannotbe
prevented [22–24]. Thus, other factors, such as C-peptide
deﬁciency, are likely to be of importance for the progres-
sion of diabetic neuropathy in type 1 diabetes. Evidence doc-
umenting signiﬁcant physiological eﬀects of C-peptide has
been presented during the latest decades. It shows that C-
peptide, in contrast to previous belief, possesses the charac-
teristics of a bioactive peptide. C-peptide binds speciﬁcally
to various cell membranes, including endothelial, renal and
nerve cells [25], with subsequent activation of an intracel-
lular signaling cascade resulting in stimulation of endothe-
lial nitric oxide synthase (eNOS) and Na+,K+-ATPase [26].
Moreover, recent data indicate that C-peptide stimulates sev-
eral transcriptional factors, as well as several neurotrophic
factors [27]. Thus, it has been demonstrated that exogenous
administration of C-peptide in replacement dose to patients
lacking endogenous C-peptide results in restoration of re-
ducedbloodﬂowinseveraltissues[28–31]andimprovement
of renal [32] and nerve function, the latter reviewed below.
It is also a long-standing clinical observation that compared
with type 1 diabetes patients in whom beta-cell secretion
ceases totally, those patients who retain a low-endogenous
C-peptide and insulin secretion are less prone to develop mi-
crovascular long-term complications involving the kidneys,
the eyes, or the nervous system [33–35].
2. CLINICAL STUDIES ON C-PEPTIDE AND
NERVE FUNCTION
To date, only a few studies on the clinical eﬀects of C-
peptide on nerve function have been performed, but several
preclinical studies indicate signiﬁcant eﬀects on diabetes-
inducednervedysfunctionandstructuralabnormalities[36–
38]. The available clinical results indicate beneﬁcial eﬀects of
C-peptide on both peripheral and autonomic nerve function
in type 1 diabetes patients. Thus, in a double-blind, placebo-
controlled study including 46 type 1 diabetes patients, with
an average age of 29 years and approximately 10 years of di-
abetes duration, and with reduced sensory nerve and mo-
tor nerve conduction velocities (NCV) but no other signs of
neuropathy, C-peptide replacement (1.8mg/day) or placebo
was given for 3 months together with the patients’ regular
insulin therapy [19]. Sensory nerve conduction velocity as-
sessedinthesuralnervebilaterally,butnotmotorNCV(per-
oneal nerve), increased gradually during the study. The in-
crease after 3 months amounted to 2.7m/s, corresponding to
an80% correctionof theinitial conductionvelocity deﬁcitin
these patients. This change was accompanied by an improve-
ment in vibration perception assessed on the dorsum of the
feet, although these patients had essentially normal percep-
tion thresholds already atbaseline. This improvement iscon-
sistent with an improved sural nerve function since vibration
perception in this anatomic region is primarily mediated via
the large ﬁbers of the sural nerve.
Theimprovementinnervefunctiondemonstratedinthis
early patient population is now conﬁrmed and extended in
a recently completed clinical trial including patients with
diabetic neuropathy [20]. The study was a double-blind,
placebo-controlled, randomized multicenter study, includ-
ing 161 type 1 diabetes patients, with an average age of 44
years and 29 years of diabetes duration and deﬁned DSPN
(according to the San Antonio criteria [3]). At baseline theirK. Ekberg and B.-L. Johansson 3
sensory nerve conduction velocity assessed in the sural nerve
(SCV) was on average 2.6 SD below normal, and follow-
ing 6 months of C-peptide replacement treatment there was
a statistically signiﬁcant improvement in SCV for the pa-
tients receiving C-peptide, amounting to 0.48 ± 0.19m/s as-
sessed as peak velocities and 0.93 ± 0.29m/s for the initial
response (the velocity change from baseline for the fastest
axon in the nerve). However, these changes were not statis-
tically signiﬁcantly diﬀerent from the change in the placebo
group. The number of responders, deﬁned as patients with
an improvement in peak SCV > 1m/s, was statistically sig-
niﬁcantly greater in the group receiving C-peptide as com-
pared to those receiving placebo (37% versus 19%, resp., p <
.032). It is noteworthy though that among the included pa-
tientssomehadsubstantialnerveconductiondeﬁcitsatbase-
line and with the study duration of no more than 6 months
it is conceivable that the patients who were relative less af-
fected at baseline may have a greater potential for improve-
ment. Thus, a subgroup analysis was performed in the subset
of patients with the least aﬀected SCV at baseline (half of the
patient population). In this group, C-peptide administration
for 6 months resulted in an improvement that was 1.03m/s
greater as compared to the change in the corresponding
placebo treated patients (P < .014). Analyzing the number
of responders in this half of the patient population revealed
that among patients receiving C-peptide, 39% demonstrated
an improvement in SCV >1m/s whereas only 5% among
the placebo treated patients showed a similar change P <
.004. Accompanying these changes in sural nerve conduc-
tion velocity there where, however, no statistically signiﬁcant
change in motor nerve conduction velocity, but there was an
improvement within the C-peptide treated patients for vi-
bration perception. There was also a trend towards an im-
provement in neurological examination scores following C-
peptide. Combining these data provides evidence of a ther-
apeutic improvement of diabetes-induced peripheral nerve
dysfunction following C-peptide administration in patients
with type 1 diabetes; 3–6 months of C-peptide replacement
to patients with early stage neuropathy resulted in approx-
imately 1.5m/s in sensory nerve conduction velocity (see
Figure 1) accompanied by other signs of nerve function im-
provements.
There is also evidence of beneﬁcial eﬀects of C-peptide
administration to type 1 patients with signs of autonomic
neuropathy. Deﬁcient autonomic nerve function may be
evaluated in patients as reduced heart rate variability (HRV)
during deep breathing, a measurement that, with a high de-
gree of reproducibility, primarily reﬂects vagal function. Pa-
tients were studied twice under normoglycemic conditions
and during 3-hours intravenous infusion of either human C-
peptide or saline in a double-blind study. At baseline HRV
was reduced 13±1% (normal reference value 24%) and dur-
ingtheC-peptide infusionwhichrestoredplasmaconcentra-
tions to physiological levels, the HRV improved to 20 ± 2%,
whilenochangewasseenaftersalineinfusion(p<.001)[39].
The heart rate brake index after a tilting maneuver was also
improved after C-peptide for 3 hours in the patients show-
ing reduced index before the study. In agreement with these
results, a 20% improvement in HRV was seen after 3 months
of C-peptide replacement in type 1 diabetes patients whereas
no change or a slight deterioration was observed in the same
patients during a placebo treatment period [32].
3. TREATMENT OF DIABETIC NEUROPATHY
T h e r ei sn oe ﬀective pharmaceutical therapy available for di-
abetic neuropathy today. The onset and the progression of
the diabetes-induced abnormalities may be delayed by main-
tenance of good glycemic control [22–24]. In the DCCT, the
incidences of diabetes neuropathy were substantially lower
in patients on intensive insulin treatment as compared to
conventional insulin therapy [23]. For the patients in the
DCCT secondary prevention group, with an average age of
28 years and a diabetes duration of 9 years, the 2% improve-
ment in HbA1c seen following 5 years of intensiﬁed insulin
treatment was accompanied by an improved SCV of 1.5m/s
whereas patients with unchanged metabolic control in the
conventional treatment group experienced a 2.2m/s reduc-
tion in SCV. Interestingly, the patients in this group are di-
rectly comparable to the patients in the ﬁrst C-peptide in-
tervention study (average age 29 years and diabetes duration
of 10 years) where 3 months of C-peptide replacement re-
sulted in 2.7m/s improvement in SCV, and it is of note that
these patients were already on an intensiﬁed insulin treat-
ment regimen [19]. The magnitude of the response follow-
ing C-peptide replacement treatment occurred completely
independent of improved glycemic control, and in fact in
top of an already good glycemic control. This suggests that
the C-peptide is in fact acting on DSPN disease-modifying
mechanisms. Impaired nerve blood ﬂow secondary to per-
turbednitricoxidemetabolism[36,38]andr educ edlev elsof
nerve Na+,K+-ATPase activity [40, 41] are both factors that
have been implicated in the pathogenesis of the DSPN [7].
The ability of C-peptide to improve endoneurial blood ﬂow
and Na+,K+- A T P a s ea c t i v i t ya sw e l la si t ss t i m u l a t i o no fn e u -
rotrophic factors as demonstrated in several animal models
of type 1 diabetes [27, 37, 40] is thus likely to contribute to
the positive eﬀects of the peptide.
In addition to improved insulin therapy, most therapeu-
tic interventions previously evaluated for DSPN have been
directed toward correction of the adverse eﬀects of hyper-
glycemia. For example, one approach involves the reduction
oftheintracellularsorbitolaccumulationbyaldosereductase
inhibitors (ARI). Although shown to have beneﬁcial eﬀects
on neuropathy [42, 43], several clinical trials involving ARIs
have been discontinued because of unacceptable adverse ef-
fects, for example, skin rash, renal toxicity, and serious hep-
atic eﬀects [44]. A new and apparently well-tolerated ARI,
ranirestat, is currently in development, and phase II data in-
dicate that its administration for 60 weeks to mostly type
2 diabetes patients has beneﬁcial eﬀects on nerve function
[45, 46]. Another compound also aiming to minimize the ef-
fects of hyperglycemia is the speciﬁc protein kinase C beta
inhibitor, ruboxistaurin, but recent clinical development has
not documented impressive clinical eﬀect [47].
It has become increasingly apparent that DSPN presents
a clear unmet medical need, and the health authorities and
representatives for patient associations have expressed their4 Experimental Diabetes Research
concern [5]. Previously, the regulatory agencies have re-
quired eﬃcacy on symptom relief and reduced wound and
amputation frequency in order to accept a new drug appli-
cation. However, it is now becoming increasingly recognized
that treatment should be started well, before the deteriora-
tion of nerve function has reached the stage of severe symp-
toms and wounds. Moreover, the treatment should not only
be directed at a symptom relief but to modify the underlying
diseasemechanisms. Inthecaseofperipheralneuropathyac-
companying type 1 diabetes, the beneﬁcial eﬀects on nerve
function following C-peptide replacement therapy may in-
dicate a new potential treatment paradigm, even though ex-
tendedclinicaltrialswillbeneededtoﬁnallyelucidateitsuse-
fulness.
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